Fecal bacteriotherapy in the treatment of recurrent Clostridium
difficile infection

a 2018

Fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection

STEBEL, Roman; Lenka VOJTILOVÁ; Michaela FREIBERGEROVÁ a Petr HUSA

Základní údaje

Originální název

Fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection

Název česky

Fekální bakterioterapie v léčbě rekurentní kolitidy vyvolané Clostridium difficile

Autoři

STEBEL, Roman (203 Česká republika, garant, domácí); Lenka VOJTILOVÁ (203 Česká republika, domácí); Michaela FREIBERGEROVÁ (203 Česká republika) a Petr HUSA (203 Česká republika, domácí)

Vydání

28th European Congress of Clinical Microbiology and Infectious Diseases, 2018

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30303 Infectious Diseases

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/18:00102898

Organizační jednotka

Lékařská fakulta

Klíčová slova česky

fekální bakterioterapie; klostridiová kolitida; střevní mikrobiom

Klíčová slova anglicky

fecal bacteriotherapy; Clostridium difficile infection; intestinal microbiome

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 10. 2018 23:51, MUDr. Roman Stebel, Ph.D.

Anotace

V originále

Background: Disruption of the natural microbial ecosystem in the colon is one of the most clinically significant adverse effects of broad-spectrum antibiotic therapy. About 20% of post-antibiotic diarrhoea cases are caused by the proliferation of toxigenic Clostridium difficile strains. Current studies of Clostridium difficile infection (CDI) pathogenesis focus on the period of increased intestinal vulnerability after completed treatment of a colitis episode until full recovery of the intestinal microbiome (about eight weeks). Relapses, readily occurring during this period, can be prevented by faecal bacteriotherapy (FBT). This method consists in transplantation of gut flora from a healthy person to the patient’s intestine to promote the recovery of natural intestinal microbiome diversity. Materials/methods: Faecal bacteriotherapy has been established at the Department of Infectious Diseases of the University Hospital Brno, Czech Republic, as a method for treating recurrent Clostridium difficile colitis since 2010. The method was applied to 71 patients during the 2-year study period (2015–2016). After treatment, the patients were followed up by means of personal visits or by phone. If colitis did not recur within eight weeks, the treatment was considered successful. Results: Overall FBT success rate was 76%, with a very low, statistically insignificant decline in recurrences. Subgroup analysis did not show any statistically significant difference in success rate between administration via nasoenteral feeding tube and rectal enema. Likewise, there were no statistically significant differences due to prior antibiotic therapy type, nor between the use of fresh and cryo-stored stool suspension. No unexpected adverse events or lethality occurred in the study period. Conclusions: Fecal bacteriotherapy is a successful therapeutic alternative for recurrent Clostridium difficile infections, recommended by international professional organizations.

Citovat

STEBEL, Roman; Lenka VOJTILOVÁ; Michaela FREIBERGEROVÁ a Petr HUSA. Fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection. In 28th European Congress of Clinical Microbiology and Infectious Diseases. 2018.

@proceedings{1419420,
   author = {Stebel, Roman and Vojtilová, Lenka and Freibergerová, Michaela and Husa, Petr},
   booktitle = {28th European Congress of Clinical Microbiology and Infectious Diseases},
   keywords = {fecal bacteriotherapy; Clostridium difficile infection; intestinal microbiome},
   language = {eng},
   title = {Fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection},
   url = {https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Stebel&id=2173&L=0&x=15&y=19},
   year = {2018}
}

TY  - CONF
ID  - 1419420
AU  - Stebel, Roman - Vojtilová, Lenka - Freibergerová, Michaela - Husa, Petr
PY  - 2018
TI  - Fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection
KW  - fecal bacteriotherapy
KW  - Clostridium difficile infection
KW  - intestinal microbiome
UR  - https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Stebel&id=2173&L=0&x=15&y=19
N2  - Background: Disruption of the natural microbial ecosystem in the colon is one of the most clinically significant adverse effects of broad-spectrum antibiotic therapy. About 20% of post-antibiotic diarrhoea cases are caused by the proliferation of toxigenic Clostridium difficile strains. Current studies of Clostridium difficile infection (CDI) pathogenesis focus on the period of increased intestinal vulnerability after completed treatment of a colitis episode until full recovery of the intestinal microbiome (about eight weeks). Relapses, readily occurring during this period, can be prevented by faecal bacteriotherapy (FBT). This method consists in transplantation of gut flora from a healthy person to the patient’s intestine to promote the recovery of natural intestinal microbiome diversity. Materials/methods: Faecal bacteriotherapy has been established at the Department of Infectious Diseases of the University Hospital Brno, Czech Republic, as a method for treating recurrent Clostridium difficile colitis since 2010. The method was applied to 71 patients during the 2-year study period (2015–2016). After treatment, the patients were followed up by means of personal visits or by phone. If colitis did not recur within eight weeks, the treatment was considered successful. Results: Overall FBT success rate was 76%, with a very low, statistically insignificant decline in recurrences. Subgroup analysis did not show any statistically significant difference in success rate between administration via nasoenteral feeding tube and rectal enema. Likewise, there were no statistically significant differences due to prior antibiotic therapy type, nor between the use of fresh and cryo-stored stool suspension. No unexpected adverse events or lethality occurred in the study period. Conclusions: Fecal bacteriotherapy is a successful therapeutic alternative for recurrent Clostridium difficile infections, recommended by international professional organizations.
ER  -

STEBEL, Roman; Lenka VOJTILOVÁ; Michaela FREIBERGEROVÁ a Petr HUSA. Fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection. In \textit{28th European Congress of Clinical Microbiology and Infectious Diseases}. 2018.

Přehled o publikaci